QPPV.COM KNOWLEDGE ASSESSMENT

Panitumumab: EGFR Biology, RAS Selection, Colorectal Cancer and Product Pharmacovigilance

Test your understanding of the concepts covered by Panitumumab: EGFR Biology, RAS Selection, Colorectal Cancer and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which causal chain best captures how severe diarrhoea may contribute to renal and electrolyte events during panitumumab therapy?

Diarrhoea causes volume loss, which can worsen renal dysfunction and electrolyte abnormalities Diarrhoea prevents all renal electrolyte excretion and causes hypermagnesaemia Diarrhoea directly activates EGFR and reverses panitumumab binding Diarrhoea has no relevance to renal injury if panitumumab is administered intravenously

Question 2 of 10 A patient develops severe panitumumab-associated skin toxicity followed by cellulitis. Which PV interpretation is most appropriate?

The cellulitis should automatically replace the skin toxicity as the only reportable event The infection may be downstream of skin-barrier disruption and should be assessed together with the preceding dermatologic event The cellulitis proves that panitumumab caused systemic immunosuppression The skin findings are irrelevant once a microbiological diagnosis is available

Question 3 of 10 How should aggregate safety analyses generally handle panitumumab monotherapy, panitumumab plus FOLFOX and panitumumab plus sotorasib?

Pool all regimens automatically because the panitumumab dose is the same Stratify by regimen and molecular population when these factors may modify risk Exclude combination regimens from all aggregate analyses Analyse only the most severe event in each treatment group

Question 4 of 10 Which laboratory pattern is most consistent with the mechanism-informed interpretation of panitumumab-associated electrolyte toxicity?

Progressive hypomagnesaemia with possible secondary hypocalcaemia and hypokalaemia Isolated persistent hypernatremia caused by increased intestinal sodium absorption Acute hypermagnesaemia caused by excessive EGFR activation Progressive thrombocytopenia with no electrolyte abnormalities

Question 5 of 10 A patient receiving panitumumab develops dyspnoea and bilateral pulmonary infiltrates. Which approach best reflects the article's PV framework?

Assume interstitial lung disease because pulmonary toxicity is listed Exclude panitumumab immediately without evaluating alternative causes Obtain imaging and evaluate infection, embolism, progression, heart failure and other treatment-related causes Classify the event as an infusion reaction unless it began during administration

Question 6 of 10 Why is dechallenge or rechallenge information valuable in a panitumumab PV case?

Recurrence after treatment resumption may provide additional causal information It establishes the tumour's RAS status without laboratory testing It proves that every event was caused by panitumumab It replaces the need to assess concomitant chemotherapy

Question 7 of 10 A patient with a KRAS-mutant mCRC tumour receives panitumumab in the United States. Which additional information is most important before concluding that the exposure was inappropriate?

The patient's EGFR expression score Whether the mutation is KRAS G12C and whether sotorasib was co-administered under the relevant indication Whether the patient previously received radiotherapy Whether the panitumumab infusion lasted more than one hour

Question 8 of 10 Which follow-up set is most appropriate for a serious skin infection occurring after several cycles of panitumumab?

Skin morphology and grade, duration, location, microbiology, neutrophil status, chemotherapy exposure and treatment interruption Only the patient's RAS mutation and EGFR expression score Only the batch number, without clinical information Only whether the infection resolved after antibiotics

Question 9 of 10 A patient develops fatigue, muscle cramps and then tetany during panitumumab therapy. Which assessment best integrates the likely clinical syndrome?

Evaluate magnesium depletion together with calcium and potassium abnormalities, treatment timing and replacement Assume an isolated psychiatric reaction because no rash is present Investigate only for EGFR expression in the tumour Conclude that tetany cannot be treatment-related because panitumumab is fully human

Question 10 of 10 Which molecular result most directly supports conventional panitumumab treatment selection in metastatic colorectal cancer?

RAS-wild-type status assessed with an appropriate validated or authorised test Any KRAS mutation, regardless of codon or treatment regimen EGFR expression alone by immunohistochemistry High tumour burden without molecular testing

QPPV.com

Panitumumab: EGFR Biology, RAS Selection, Colorectal Cancer and Product Pharmacovigilance

Cookie Settings